Cytosorbents (CTSO) Cash from Operations (2010 - 2026)

Cytosorbents (CTSO) has reported Cash from Operations for 17 consecutive years, with -$583000.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Cash from Operations rose 61.37% year-over-year to -$583000.0; the trailing twelve-month figure through Jun 2026 stood at -$9.1 million (up 6.46% YoY), and the FY2025 full-year result was -$12.4 million, up 14.22% from the prior year.
• Cash from Operations rose to -$583000.0 in Q2 2026 per CTSO's latest filing, from -$1.2 million in the prior quarter.
• Across five years, Cash from Operations topped out at -$583000.0 in Q2 2026 and bottomed at -$8.1 million in Q1 2022.
• Historically, Cash from Operations has averaged -$4.4 million across 5 years, with a median of -$4.8 million in 2024.
• The sharpest annual moves came in 2022 and 2025: Cash from Operations slumped 294.84% in 2022, then soared 68.52% in 2025.
• Over 5 years, Cash from Operations stood at -$5.3 million in 2022, then slipped by 19.98% to -$6.4 million in 2023, then surged by 63.46% to -$2.3 million in 2024, then slumped by 106.11% to -$4.8 million in 2025, then jumped by 87.92% to -$583000.0 in 2026.
• According to Business Quant data, Cash from Operations over the past three periods registered -$583000.0, -$1.2 million, and -$4.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.